NA Adamson

Dr. NA Adamson


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
FHFatime Hawchar
Fatime Hawchar
CRCristina Rao
Cristina Rao
AAAli Akil
Ali Akil
YMYatin Mehta
Yatin Mehta
CRChristopher Rugg
Christopher Rugg
ZMZsolt Molnar
Zsolt Molnar
Hemodynamic instability due to dysregulated host response is a life-threatening condition requiring vasopressors and vital organ support. Hemoadsorption with Cytosorb has proven to be effective in reducing cytokines and possibly in attenuating the devastating effects of the cytokine storm originating from the immune over-response to the initial insult. We reviewed the PubMed database to assess evidence of the impact of Cytosorb on norepinephrine needs in the critically ill. We further analyzed those studies including data on control cohorts in a comparative pooled analysis, defining a treatment effect as the standardized mean differences in relative reductions in vasopressor dosage at 24 h. The literature search returned 33 eligible studies. We found evidence of a significant reduction in norepinephrine requirement after treatment: median before, 0.55 (IQR: 0.39–0.90); after, 0.09 (0.00–0.25) μg/kg/min, p < 0.001. The pooled effect size at 24 h was large, though characterized by high heterogeneity. In light of the importance of a quick resolution of hemodynamic instability in the critically ill, further research is encouraged to enrich knowledge on the potentials of the therapy.

12 May 2026 in Journal of Anesthesia, Analgesia and Critical Care
Verified
Journal Article
Open access
PDF file
RPRAJIB PAUL
RAJIB PAUL
AAAbdul Samad Ansari
Abdul Samad Ansari
DBDavid Andrés Ballesteros
David Andrés Ballesteros
NANA Adamson
NA Adamson
TKTeresa Klaus
Teresa Klaus
Patrick M HonorePatrick M Honore
Patrick M Honore
This scoping review explores the potential effects of various extracorporeal technologies on the clearance of commonly used drugs. Understanding these inte

14 July 2026 in Critical Care Explorations
Verified
Journal Article
Open access
TKTeresa Klaus
Teresa Klaus
PHPatrick M. Honoré
Patrick M. Honoré
Gabriella BottariGabriella Bottari
Gabriella Bottari
SRSilvia De Rosa
Silvia De Rosa
DKDetlef Kindgen-Milles
Detlef Kindgen-Milles
TNThomas D. Nolin
Thomas D. Nolin
OBJECTIVE: CytoSorb (CS) hemoadsorption is increasingly used in critical care and cardiac surgery to remove inflammatory mediators and select drugs. This systematic review aimed to summarize available evidence on intentional drug removal as well as unintentional drug removal during CS therapy. DATA SOURCES: PubMed, congress abstracts, and CytoSorbents online literature database. STUDY SELECTION: Eligible studies included benchtop, animal, and human pharmacokinetic investigations of drug removal during CS therapy as well as clinical reports describing CS use for drug overdose. DATA EXTRACTION: Data from the eligible studies were extracted independently by two authors into Microsoft Excel. DATA SYNTHESIS: Data were identified for drugs across multiple therapeutic classes, including analgesics, antiarrhythmics, anticonvulsants, antidepressants, antihypertensives, anti-infectives, antithrombotics, anxiolytics, and immunosuppressants. Drugs were categorized into low (< 30%), moderate (30–60%), or high (> 60%) removal rate, or by the relative increase in clearance attributable to CS: negligible (< 25%), low (25–100%), moderate (100–400%), or high (> 400%). Based on the assembled data and considering drug-, patient-, and circuit-specific factors, general dosing recommendations for concomitant medications were developed. CONCLUSIONS: CS therapy can alter drug concentrations for select agents with variable clinical relevance. CS can reduce perioperative bleeding risk through antithrombotic removal and treat certain drug overdoses. Unintentional drug removal during CS therapy may occur and practical guidance is provided for drugs with known susceptibility to removal.